THE Food and Drug Administration (FDA) yesterday called on doctors and other medical professionals pushing for the use of anti-parasitic drug Ivermectin to rethink their position in encouraging their patients to use it against the coronavirus disease (COVID-19).
In a television interview, FDA Director General Eric Domingo said he is appealing to the sense of responsibility of doctors to avoid endorsing alleged COVID-19 treatments sans sufficient scientific evidences.
“As health workers, it is our responsibility to make our patients understand what types of medicines are we giving them and on its possible effects to their bodies. It will ultimately depend on the wisdom of the doctors, their examination of their patients, if they can use off-label drugs (like Ivermectin),” said Domingo.
The FDA chief reiterated there are no approved Ivermectin products in the country, except those for animal use.
Currently pending is the application of Lloyd Laboratories Inc. for a certificate product registration (CPR) before the FDA.
“There is a possibility that it will be useful or not. Why not just wait for the result of the trials,” said Domingo.
In a separate statement, the Department of Health (DOH) said recent controlled trials of Ivermectin showed that it did not significantly reduce the risk of mortality among patients with mild to severe COVID-19 cases.
Ivermectin, it added, was not associated with a definite benefit of other clinically important outcomes, such as clinical improvement at Day 6-10, clinical deterioration, and need for mechanical ventilation.